奥妥珠单抗联合伊布替尼诱导后按MRD驱动策略治疗初治CLL的II期研究
这项单臂多中心II期试验纳入135例初治CLL患者,先接受9个月奥妥珠单抗联合伊布替尼诱导,再根据第9个月骨髓MRD状态分配后续6个月治疗。最常见血液学不良事件为血小板减少,未发生治疗相关死亡。
要点
- 最常见血液学不良事件为血小板减少,未发生治疗相关死亡。
核心结论
- 奥妥珠单抗联合伊布替尼诱导后按MRD驱动策略在初治CLL中安全且有活性。
- 若随访中MRD应答维持,该策略可能成为初治CLL的一线选择,但仍需随机证据。
研究设计与样本
- 单臂、多中心、II期试验,在法国27家大学医院、综合医院和专科癌症中心开展。
- 纳入135例≥18岁、初治、免疫表型确诊B细胞CLL、ECOG评分<2、Binet C期或伴活动性疾病的A/B期、无17p缺失或p53突变、医学上适合的患者。
主要发现
- 第1-9个月最常见血液学不良事件为血小板减少(133例中45例[34%]为1-2级),第9-15个月为130例中43例(33%)为1-2级。
- 第1-9个月最常见非血液学不良事件为输注相关反应(83例[62%]为1-2级),第9-15个月为胃肠道疾病(62例[48%]为1-2级)。
- 共发生49例严重不良事件,最常见为感染(10例)、心脏事件(8例)和血液学事件(8例);无治疗相关死亡。
关键数值与推荐
- 诱导期:所有参与者接受奥妥珠单抗1000 mg静脉输注共8次(6个4周周期)及口服伊布替尼420 mg每日一次,共9个月。
临床怎么用
- 对初治CLL患者,可考虑9个月奥妥珠单抗联合伊布替尼诱导,随后根据第9个月骨髓MRD状态选择后续6个月治疗。
- 该策略仍需随机证据支持,目前应结合随访中MRD演变评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with chronic lymphocytic leukaemia, achievement of a complete response with minimal residual disease of less than 0·01% (ie, <1 chronic lymphocytic leukaemia cell per 10 000 leukocytes) in bone marrow has been associated with improved progression-free survival. We aimed to explore the activity of induction therapy for 9 months with obinutuzumab and ibrutinib, followed up with a minimal residual disease-driven therapeutic strategy for 6 additional months, in previously untreated patients. METHODS: We did a single-arm, phase 2 trial in 27 university hospitals, general hospitals, and specialist cancer centres in France. Eligible patients were at least 18 years old and previously untreated, and had immunophenotypically confirmed B-cell chronic lymphocytic leukaemia; an Eastern Cooperative Oncology Group (ECOG) performance status score of less than 2; a Binet stage C according to IWCLL 2008 criteria or Binet stage A and B with active disease; no 17p deletion or absence of p53 mutation; and were considered medically fit. In the first part of the study (induction phase), all participants received eight intravenous infusions of obinutuzumab 1000 mg over six 4-weekly cycles and oral ibrutinib 420 mg once per day for 9 months. In part 2, after assessment on day 1 of month 9, patients with a complete response and bone marrow minimal residual disease of less than 0·01% received only oral ibrutinib 420 mg once per day for 6 additional months. Patients with a partial response, or with a complete response and bone marrow minimal residual disease of 0·01% or more, received 6 months of four 4-weekly cycles of intravenous fludarabine, cyclophosphamide, and obinutuzumab 1000 mg, alongside continuing ibrutinib 420 mg once per day. The primary endpoint was the proportion of patients achieving a complete response with bone marrow minimal residual disease less than 0·01% on day 1 of month 16 assessed by intention to treat (ITT). This trial is registered with ClinicalTrials.gov (number NCT02666898) and is still open for follow-up. FINDINGS: Between Oct 27, 2015, and May 16, 2017, 135 patients were enrolled. After induction treatment (day 1 of month 9), 130 patients were evaluable, of which ten (8%) achieved a complete response with bone marrow minimal residual disease of less than 0·01% and were assigned to ibrutinib, and 120 (92%) were assigned to ibrutinib plus fludarabine, cyclophosphamide, and obinutuzumab. After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%. The most common haematological adverse event was thrombocytopenia (in 45 [34%] of 133 patients at grade 1-2 in months 1-9 and in 43 [33%] of 130 patients at grade 1-2 in months 9-15). The most common non-haematological adverse events were infusion-related reactions (in 83 [62%] patients at grade 1-2 in months 1-9) and gastrointestinal disorders (in 62 [48%] patients at grades 1 and 2 in months 9-15). 49 serious adverse events occurred, most frequently infections (ten), cardiac events (eight), and haematological events (eight). No treatment-related deaths occurred. INTERPRETATION: Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease driven strategy is safe and active in patients with previously untreated chronic lymphocytic leukaemia. With longer follow-up, including assessing the evolution of minimal residual disease, if response is maintained, this strategy could be an option in the first-line setting in patients with chronic lymphocytic leukaemia, although randomised evidence is needed. FUNDING: Roche, Janssen.
引用
- Michallet AS, Dilhuydy MS, Subtil F, et al. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019. PMID: 31324600. doi:10.1016/S2352-3026(19)30113-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。